AP2012006053A0 - Pure peg-lipid conjugates. - Google Patents
Pure peg-lipid conjugates.Info
- Publication number
- AP2012006053A0 AP2012006053A0 AP2012006053A AP2012006053A AP2012006053A0 AP 2012006053 A0 AP2012006053 A0 AP 2012006053A0 AP 2012006053 A AP2012006053 A AP 2012006053A AP 2012006053 A AP2012006053 A AP 2012006053A AP 2012006053 A0 AP2012006053 A0 AP 2012006053A0
- Authority
- AP
- ARIPO
- Prior art keywords
- lipid conjugates
- pure peg
- peg
- pure
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
- C08L63/10—Epoxy resins modified by unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21762709P | 2009-06-02 | 2009-06-02 | |
| US28406509P | 2009-12-12 | 2009-12-12 | |
| PCT/US2010/001590 WO2010141069A2 (en) | 2009-06-02 | 2010-06-01 | Pure peg-lipid conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2012006053A0 true AP2012006053A0 (en) | 2012-02-29 |
Family
ID=43298359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006053A AP2012006053A0 (en) | 2009-06-02 | 2010-06-01 | Pure peg-lipid conjugates. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110040113A1 (xx) |
| EP (1) | EP2437756A2 (xx) |
| JP (1) | JP2012528857A (xx) |
| KR (1) | KR20120039564A (xx) |
| CN (1) | CN102665685A (xx) |
| AP (1) | AP2012006053A0 (xx) |
| AU (1) | AU2010257181A1 (xx) |
| BR (1) | BRPI1010175A2 (xx) |
| CA (1) | CA2763819A1 (xx) |
| CL (1) | CL2011003049A1 (xx) |
| CO (1) | CO6511284A2 (xx) |
| IL (1) | IL216719A0 (xx) |
| MX (1) | MX2011012823A (xx) |
| WO (1) | WO2010141069A2 (xx) |
| ZA (1) | ZA201109366B (xx) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| US20120232169A1 (en) * | 2011-03-07 | 2012-09-13 | Biozone Pharmaceuticals, Inc. | Highly monodisperse branched peg-lipid conjugates |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| US8883177B2 (en) | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
| US8575380B2 (en) * | 2011-10-17 | 2013-11-05 | Nof Corporation | Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome |
| US11458199B2 (en) | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
| ES2881671T3 (es) | 2012-08-21 | 2021-11-30 | Opko Pharmaceuticals Llc | Formulaciones de liposomas |
| CA2914472C (en) | 2012-08-24 | 2019-09-03 | Ashim K. Mitra | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
| WO2015021044A1 (en) * | 2013-08-05 | 2015-02-12 | University Of Rochester | Compositions and methods for stimuli-responsive release of a therapeutic agent |
| CN105792850A (zh) * | 2013-12-05 | 2016-07-20 | 念·吴 | 聚合物-碳水化合物的缀合物的药物转递技术 |
| JP6629736B2 (ja) * | 2013-12-20 | 2020-01-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む、細胞を結合するのに有用な化合物 |
| EP3084433B1 (en) | 2013-12-20 | 2020-03-18 | Roche Diagnostics GmbH | Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety |
| CA2929972C (en) * | 2013-12-20 | 2018-07-24 | F. Hoffmann-La Roche Ag | Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell |
| US9517270B2 (en) | 2014-12-08 | 2016-12-13 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
| US10064954B2 (en) * | 2015-06-23 | 2018-09-04 | Nian Wu | Polymer-cyclodextrin-lipid conjugates |
| EP3950003A1 (en) | 2015-09-14 | 2022-02-09 | The Board of Regents of the University of Texas System | Lipocationic dendrimers and uses thereof |
| CN106905120B (zh) * | 2015-12-21 | 2020-04-28 | 北京键凯科技股份有限公司 | Y型多缩乙二醇衍生物及其制备方法 |
| US10918694B2 (en) | 2016-02-29 | 2021-02-16 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
| JP7080826B2 (ja) | 2016-05-16 | 2022-06-06 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| CN115919769A (zh) | 2016-05-16 | 2023-04-07 | 德克萨斯大学系统董事会 | 用于作为纳米粒递送tRNA的组合物及其使用方法 |
| US11905367B2 (en) | 2018-03-20 | 2024-02-20 | Nof Corporation | Branched monodispersed polyethylene glycol, intermediate and methods for producing same |
| CA3095299A1 (en) | 2018-03-29 | 2019-10-03 | Nof Corporation | Method for purifying trityl group-containing monodispersed polyethylene glycol |
| WO2019191597A1 (en) * | 2018-03-30 | 2019-10-03 | The Board Of Regents Of The University Of Oklahoma | Very long chain saturated fatty acid compounds, compositions containing same, and methods of use |
| GB2617429B (en) | 2018-09-04 | 2023-12-27 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
| WO2020051223A1 (en) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| JP6805385B1 (ja) * | 2020-08-31 | 2020-12-23 | ジェイ−ネットワーク，インコーポレイテッド | 表皮内の保湿関連物質の発現増強剤 |
| JP6860739B1 (ja) * | 2020-11-20 | 2021-04-21 | ジェイ−ネットワーク，インコーポレイテッド | 表皮内の抗酸化物質の発現増強剤 |
| CN114685778B (zh) * | 2020-12-30 | 2023-10-17 | 苏州艾博生物科技有限公司 | 长循环阳离子脂质体的合成方法 |
| CA3206911A1 (en) | 2021-02-08 | 2022-08-11 | Sang M. Lee | Unsaturated dendrimers compositions,related formulations, and methods of use thereof |
| WO2023273364A1 (zh) | 2021-06-30 | 2023-01-05 | 天津键凯科技有限公司 | 聚乙二醇脂质及其应用 |
| CN113461929B (zh) * | 2021-07-13 | 2023-04-21 | 浙江倍合德制药有限公司 | 一种tpgs系列产品的精制提纯方法 |
| CN114507342B (zh) * | 2022-03-18 | 2024-03-19 | 江苏东南纳米材料有限公司 | 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法 |
| WO2023196445A1 (en) * | 2022-04-05 | 2023-10-12 | Capstan Therapeutics, Inc. | Peg-lipids and lipid nanoparticles |
| CN114524943B (zh) * | 2022-04-22 | 2022-09-16 | 天津凯莱英制药有限公司 | 聚乙二醇-甘油衍生物及其中间体各自的制备方法 |
| WO2024105071A1 (en) * | 2022-11-15 | 2024-05-23 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-dimyristoyl-glycerol compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
| CN116178733B (zh) * | 2023-03-03 | 2023-08-01 | 浙江博美生物技术有限公司 | 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| AU2004272646B2 (en) * | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
| WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| CA2629330C (en) * | 2004-11-12 | 2018-05-22 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| CA2705797A1 (en) * | 2007-11-14 | 2009-05-22 | The Regents Of The University Of California | Sterol-modified amphiphilic lipids |
-
2010
- 2010-06-01 MX MX2011012823A patent/MX2011012823A/es not_active Application Discontinuation
- 2010-06-01 BR BRPI1010175A patent/BRPI1010175A2/pt not_active Application Discontinuation
- 2010-06-01 KR KR1020117031713A patent/KR20120039564A/ko not_active Application Discontinuation
- 2010-06-01 CA CA2763819A patent/CA2763819A1/en not_active Abandoned
- 2010-06-01 US US12/802,197 patent/US20110040113A1/en not_active Abandoned
- 2010-06-01 EP EP10783699A patent/EP2437756A2/en not_active Withdrawn
- 2010-06-01 AU AU2010257181A patent/AU2010257181A1/en not_active Abandoned
- 2010-06-01 WO PCT/US2010/001590 patent/WO2010141069A2/en active Application Filing
- 2010-06-01 CN CN2010800303714A patent/CN102665685A/zh active Pending
- 2010-06-01 JP JP2012513928A patent/JP2012528857A/ja active Pending
- 2010-06-01 AP AP2012006053A patent/AP2012006053A0/xx unknown
-
2011
- 2011-12-01 IL IL216719A patent/IL216719A0/en unknown
- 2011-12-02 CL CL2011003049A patent/CL2011003049A1/es unknown
- 2011-12-20 ZA ZA2011/09366A patent/ZA201109366B/en unknown
- 2011-12-30 CO CO11181678A patent/CO6511284A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012528857A (ja) | 2012-11-15 |
| KR20120039564A (ko) | 2012-04-25 |
| CO6511284A2 (es) | 2012-08-31 |
| CL2011003049A1 (es) | 2012-07-13 |
| ZA201109366B (en) | 2012-08-29 |
| US20110040113A1 (en) | 2011-02-17 |
| IL216719A0 (en) | 2012-02-29 |
| EP2437756A2 (en) | 2012-04-11 |
| BRPI1010175A2 (pt) | 2016-03-29 |
| AU2010257181A1 (en) | 2012-01-12 |
| WO2010141069A2 (en) | 2010-12-09 |
| MX2011012823A (es) | 2012-06-25 |
| WO2010141069A3 (en) | 2012-04-12 |
| CA2763819A1 (en) | 2010-12-09 |
| CN102665685A (zh) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2012006053A0 (en) | Pure peg-lipid conjugates. | |
| AP2012006216A0 (en) | Benzimidazole-imidazole derivatives. | |
| IL211180B (en) | Attached polyethylene glycol and docetaxel | |
| ZA201106050B (en) | Dye-polymers formulations | |
| GB0919210D0 (en) | Formulations | |
| AP2011005894A0 (en) | 5-alkynyl-pyridines. | |
| GB2476715B (en) | Eco-F.E.W.L. | |
| EP2406304A4 (en) | ANTHRACYCLINE-LIPID CONJUGATES WITH GABA BINDING | |
| LU91562B1 (en) | Hydroquinone derivatives. | |
| AP2011005789A0 (en) | Sulfamoyl-phenyl-ureido benzamidine-derivatives asantimalarial agents. | |
| AP2011005899A0 (en) | Plaswall. | |
| GB0906023D0 (en) | Insulin-Nanoparticle conjugates | |
| IL217390A0 (en) | Formulations | |
| RS60336B1 (sr) | Konjugati proteina i polimera | |
| EP2313457A4 (en) | PEPTIDPOLYMERKONJUGATE | |
| GB201020866D0 (en) | . | |
| GB0902615D0 (en) | . | |
| GB0903183D0 (en) | . | |
| GB0913073D0 (en) | . | |
| GB0903558D0 (en) | . | |
| GB0907991D0 (en) | . | |
| GB0913633D0 (en) | . | |
| GB0918988D0 (en) | . | |
| GB0903713D0 (en) | Envelope | |
| GB0921822D0 (en) | Envelope |